Ana Maria Fortuna

Ana Maria Fortuna

Auto-generated profile, based on publicly available information

Ana Maria Fortuna

Unidade Multidisciplinar de Investigação Biomédica (UMIB) Instituto de Ciências Biomédicas Abel Salazar (ICBAS) Universidade do Porto Porto Portugal

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2000 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
MOMichael Oldridge
Michael Oldridge
AFAna M Fortuna
Ana M Fortuna
MMMonika Maringa
Monika Maringa
PPPeter Propping
Peter Propping
SMSahar Mansour
Sahar Mansour
AWAndrew O. M. Wilkie
Andrew O. M. Wilkie

26 August 2015 in European Journal of Human Genetics
Verified
Journal Article
Closed access
DSDDD Study
DDD Study
DKDavid A Koolen
David A Koolen
RPRolph Pfundt
Rolph Pfundt
KLKatrin Linda
Katrin Linda
GBGea Beunders
Gea Beunders
BVBert Ba de Vries
Bert Ba de Vries

20 October 2009 in Journal of Medical Genetics
Verified
Journal Article
Closed access
PDF file
YVYvonne J Vos
Yvonne J Vos
HWHermien E K de Walle
Hermien E K de Walle
KBKrista K Bos
Krista K Bos
JSJenneke A Stegeman
Jenneke A Stegeman
ABAnnelies M Ten Berge
Annelies M Ten Berge
RHRobert M W Hofstra
Robert M W Hofstra
Objectives: To develop a comprehensive mutation analysis system with a high rate of detection, to develop a tool to predict the chance of detecting a mutation in the L1CAM gene, and to look for genotype–phenotype correlations in the X-linked recessive disorder, L1 syndrome. Methods: DNA from 367 referred patients was analysed for mutations in the coding sequences of the gene. A subgroup of 100 patients was also investigated for mutations in regulatory sequences and for large duplications. Clinical data for 106 patients were collected and used for statistical analysis. Results: 68 different mutations were detected in 73 patients. In patients with three or more clinical characteristics of L1 syndrome, the mutation detection rate was 66% compared with 16% in patients with fewer characteristics. The detection rate was 51% in families with more than one affected relative, and 18% in families with one affected male. A combination of these two factors resulted in an 85% detection rate (OR 10.4, 95% CI 3.6 to 30.1). The type of mutation affects the severity of L1 syndrome. Children with a truncating mutation were more likely to die before the age of 3 than those with a missense mutation (52% vs 8%; p=0.02). Conclusions: We developed a comprehensive mutation detection system with a detection rate of almost 20% in unselected patients and up to 85% in a selected group. Using the patients' clinical characteristics and family history, clinicians can accurately predict the chance of finding a mutation. A genotype-phenotype correlation was confirmed. The occurrence of (maternal) germline mosaicism was proven.

11 January 2016 in Journal of Bone and Mineral Research
Verified
Journal Article
Open access
PDF file
IFIgor Fijalkowski
Igor Fijalkowski
EGEllen Geets
Ellen Geets
ESEllen Steenackers
Ellen Steenackers
VHViviane Van Hoof
Viviane Van Hoof
FRFeliciano J Ramos
Feliciano J Ramos
EBEveline Boudin
Eveline Boudin
Mutations in the LRP4 gene, coding for a Wnt signaling coreceptor, have been found to cause several allelic conditions. Among these, two are characterized by a strong skeletal involvement, namely sclerosteosis and Cenani-Lenz syndrome. In this work, we evaluated the role of LRP4 in the pathophysiology of these diseases. First, we report a novel LRP4 mutation, leading to the substitution of arginine at position 1170 in glutamine, identified in a patient with sclerosteosis. This mutation is located in the central cavity of the third β-propeller domain, which is in line with two other sclerosteosis mutations we previously described. Reporter assays demonstrate that this mutation leads to impaired sclerostin inhibition of Wnt signaling. Moreover, we compared the effect of this novel variant to mutations causing Cenani-Lenz syndrome and show that impaired membrane trafficking of the LRP4 protein is the likely mechanism underlying Cenani-Lenz syndrome. This is in contrast to sclerosteosis mutations, previously shown to impair the binding between LRP4 and sclerostin. In addition, to better understand the biology of LRP4, we investigated the circulating sclerostin levels in the serum of a patient suffering from sclerosteosis owing to a LRP4 mutation. We demonstrate that impaired sclerostin binding to the mutated LRP4 protein leads to dramatic increase in circulating sclerostin in this patient. With this study, we provide the first evidence suggesting that LRP4 is responsible for the retention of sclerostin in the bone environment in humans. These findings raise potential concerns about the utility of determining circulating sclerostin levels as a marker for other bone-related parameters. Although more studies are needed to fully understand the mechanism whereby LRP4 facilitates sclerostin action, it is clear that this protein represents a potent target for future osteoporosis therapies and an interesting alternative for the antisclerostin treatment currently under study. © 2016 American Society for Bone and Mineral Research.

1 April 1999 in Blood Cells, Molecules, and Diseases
Verified
Journal Article
Closed access
LLLucia Lacerdaa
Lucia Lacerdaa
Fernando A. ArosaFernando A. Arosa
Fernando A. Arosa
RLRosa Lacerdac
Rosa Lacerdac
JCJose Manuel Cabeda
Jose Manuel Cabeda
GPGraça Porto
Graça Porto
MSMaria de Sousa
Maria de Sousa

5 March 2015 in Journal of Human Genetics
Verified
Journal Article
Closed access
PDF file
JOJorge Oliveira
Jorge Oliveira
LNLuís Negrão
Luís Negrão
IFIsabel Fineza
Isabel Fineza
RTRicardo Taipa
Ricardo Taipa
MMManuel Melo-Pires
Manuel Melo-Pires
MSMário Sousa
Mário Sousa